Healthcare provider profile · identity verified

Crystal Grace Roe, MD

Allopathic & Osteopathic Physicians|Family Medicine · GARLAND, TX · NPI 1861871857

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Crystal Grace Roe, MD received $91.33 in general payments during 2025 across 4 reported records.

Supernus Pharmaceuticals, Inc. accounted for 45.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$91.33

4 reported records · 3 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$41.30	45.2%	2	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$27.86	30.5%	1	2025
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$22.17	24.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$91.33	4

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$41.30	2	2025
Source payment records 2025-06-17 · Supernus Pharmaceuticals, Inc. · $19.52 · Open Payments source 2025-10-14 · Supernus Pharmaceuticals, Inc. · $21.78 · Open Payments source
Cologuard Collection Kit Normalized: cologuard collection kit	Device	Exact Sciences Corporation	$27.86	1	2025
Source payment records 2025-05-12 · Exact Sciences Corporation · $27.86 · Open Payments source
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$22.17	1	2025
Source payment records 2025-04-14 · Novo Nordisk Inc · $22.17 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	156	41

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	767	265
Levothyroxine Sodium	Levothyroxine Sodium	663	153
Gabapentin	Gabapentin	550	139
Amlodipine Besylate	Amlodipine Besylate	540	170
Losartan Potassium	Losartan Potassium	482	155
Lisinopril	Lisinopril	361	123
Trazodone Hcl	Trazodone Hcl	324	90
Metformin Hcl	Metformin Hcl	314	98
Montelukast Sodium	Montelukast Sodium	307	97
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	291	40
Metoprolol Succinate	Metoprolol Succinate	236	85
Bupropion Xl	Bupropion Hcl	235	53
Furosemide	Furosemide	235	79
Albuterol Sulfate Hfa	Albuterol Sulfate	234	77
Omeprazole	Omeprazole	229	71
Carvedilol	Carvedilol	224	70
Rosuvastatin Calcium	Rosuvastatin Calcium	213	57
Pantoprazole Sodium	Pantoprazole Sodium	199	66
Duloxetine Hcl	Duloxetine Hcl	178	54
Meloxicam	Meloxicam	174	74
Sertraline Hcl	Sertraline Hcl	173	50
Amitriptyline Hcl	Amitriptyline Hcl	166	55
Potassium Chloride	Potassium Chloride	160	52
Citalopram Hbr	Citalopram Hydrobromide	159	41
Ozempic	Semaglutide	156	41
Fluticasone Propionate	Fluticasone Propionate	151	50
Alendronate Sodium	Alendronate Sodium	146	37
Metoprolol Tartrate	Metoprolol Tartrate	144	44
Famotidine	Famotidine	132	45
Hydroxyzine Hcl	Hydroxyzine Hcl	132	52
Farxiga	Dapagliflozin Propanediol	130	33
Tamsulosin Hcl	Tamsulosin Hcl	130	43
Venlafaxine Hcl Er	Venlafaxine Hcl	128	30
Simvastatin	Simvastatin	127	41
Tizanidine Hcl	Tizanidine Hcl	127	40
Allopurinol	Allopurinol	124	29
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	122	27
Escitalopram Oxalate	Escitalopram Oxalate	120	32
Donepezil Hcl	Donepezil Hcl	118	31
Eliquis	Apixaban	117	30
Hydrochlorothiazide	Hydrochlorothiazide	109	41
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	108	33
Mirtazapine	Mirtazapine	108	32
Buspirone Hcl	Buspirone Hcl	105	22
Celecoxib	Celecoxib	105	27
Quetiapine Fumarate	Quetiapine Fumarate	102	21
Ropinirole Hcl	Ropinirole Hcl	100	21
Clopidogrel	Clopidogrel Bisulfate	95	37
Jardiance	Empagliflozin	87	31
Tramadol Hcl	Tramadol Hcl	87	30
Januvia	Sitagliptin Phosphate	84	22
Naproxen	Naproxen	75	36
Synthroid	Levothyroxine Sodium	74	18
Pravastatin Sodium	Pravastatin Sodium	71	23
Benazepril Hcl	Benazepril Hcl	70	13
Metformin Hcl Er	Metformin Hcl	68	24
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	23
Pregabalin	Pregabalin	66	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	64	51
Symbicort	Budesonide/Formoterol Fumarate	64	20
Memantine Hcl	Memantine Hcl	60	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	54	46
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	18
Levetiracetam	Levetiracetam	50	11
Esomeprazole Magnesium	Esomeprazole Magnesium	48	13
Methocarbamol	Methocarbamol	48	13
Doxycycline Hyclate	Doxycycline Hyclate	46	37
Triamcinolone Acetonide	Triamcinolone Acetonide	46	25
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	45	suppressed
Ventolin Hfa	Albuterol Sulfate	45	16
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	43	suppressed
Xarelto	Rivaroxaban	43	16
Finasteride	Finasteride	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	14
Irbesartan	Irbesartan	42	13
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	41	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	40	suppressed
Ondansetron Odt	Ondansetron	39	21
Lovastatin	Lovastatin	38	suppressed
Baclofen	Baclofen	36	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	36	11
Mounjaro	Tirzepatide	35	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	33	12
Ezetimibe	Ezetimibe	32	suppressed
Glimepiride	Glimepiride	32	12
Hydralazine Hcl	Hydralazine Hcl	32	13
Nortriptyline Hcl	Nortriptyline Hcl	30	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	29	suppressed
Azithromycin	Azithromycin	28	28
Spironolactone	Spironolactone	28	13
Venlafaxine Hcl	Venlafaxine Hcl	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Divalproex Sodium	Divalproex Sodium	25	suppressed
Fluconazole	Fluconazole	25	18
Nifedipine Er	Nifedipine	23	suppressed
Atenolol	Atenolol	22	suppressed
Fenofibrate	Fenofibrate	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	20
Topiramate	Topiramate	22	suppressed
Valsartan	Valsartan	22	suppressed
Humalog Kwikpen U-100	Insulin Lispro	21	suppressed
Nystatin	Nystatin	21	18
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Levemir Flexpen	Insulin Detemir	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Brilinta	Ticagrelor	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Nitroglycerin	Nitroglycerin	18	13
Prednisone	Prednisone	18	15
Sotalol	Sotalol Hcl	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Bumetanide	Bumetanide	16	suppressed
Dexlansoprazole Dr	Dexlansoprazole	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Torsemide	Torsemide	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Methylprednisolone	Methylprednisolone	15	15
Metoclopramide Hcl	Metoclopramide Hcl	15	suppressed
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Glipizide	Glipizide	14	suppressed
Movantik	Naloxegol Oxalate	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Levofloxacin	Levofloxacin	13	suppressed
Oxcarbazepine	Oxcarbazepine	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Tresiba Flextouch U-200	Insulin Degludec	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Admelog Solostar	Insulin Lispro	12	suppressed
Amoxicillin	Amoxicillin	12	11
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Diazepam	Diazepam	12	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	12	suppressed
Praluent Pen	Alirocumab	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Bethanechol Chloride	Bethanechol Chloride	11	suppressed
Carbamazepine	Carbamazepine	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Linzess	Linaclotide	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Terbinafine Hcl	Terbinafine Hcl	11	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$91.33 · 4 records	Supernus Pharmaceuticals, Inc.	Cologuard Collection Kit, Qelbree, Wegovy	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error